Deleted ICD-10-PCS Code XW01X27 Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
- Deleted — Not Valid for Claims
- Valid FY 2022–2026
- Deleted in FY 2027
XW01X27 is a deleted ICD-10-PCS code, removed from the code set effective October 1, 2026. It was valid for introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 on inpatient discharges from October 1, 2021 through September 30, 2026, and later discharges must use a current code. The CMS conversion table maps it to 3E01XGF.
Replacement Codes for XW01X27
The CMS ICD-10-PCS conversion table maps XW01X27 to this code. Confirm the choice against the procedure documentation and the code page's table.
- 3E01XGF Introduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach
Current Codes Starting With XW01
Active FY 2027 codes that share the first 4 characters of XW01X27 (same table and body part).
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
- XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
- XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
- XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
Code History
Questions About XW01X27
Is XW01X27 still a valid ICD-10-PCS code?
No. XW01X27 was deleted from ICD-10-PCS effective October 1, 2026, with the FY 2027 code set. It cannot be reported for inpatient discharges on or after that date.
What replaced XW01X27?
The CMS ICD-10-PCS conversion table maps XW01X27 to 3E01XGF. Confirm it matches the procedure documentation before you use it; a conversion is a starting point, not an automatic substitution.
Can I still use XW01X27 for older discharges?
Yes, for inpatient discharges from October 1, 2021 through September 30, 2026. ICD-10-PCS codes are assigned by the code set in effect on the date of discharge, so a corrected or late claim for a discharge in that window still uses XW01X27.